CHEYENNE — Despite pushback from several nearby landowners, the Laramie County Board of County Commissioners voted last week to approve the site plan for a new 150-foot-tall cell tower in ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL ...

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The ...

LENOX — The Zoning Board of Appeals has opened its review of the proposal for a new cell tower that would fill widespread wireless signal gaps in town. The ZBA held part one of its public hearing ...

Carlos Fernandez, a former senior F.B.I. agent in charge of New York’s counterterrorism division, said the agents had to take seriously the possibility of sleeper cells in the United States ...

A robust clinical development programme for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell ...

Finally, cells are filtered through a 70 µm cell strainer, after which ~5 million cells are analysed using flow cytometry, 1 million cells are plated for subsequent culture and remaining cells are ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma Provided by PR Newswire Jun 13, 2025, 8:00:00 AM ...

While flow cytometry allows for quantification of these antigen-specific B-cells, it does not distinguish between cell-surface and internalized antigen. Therefore, confocal microscopy was employed to ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with metastatic melanoma.